Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
7
×
cancer immunotherapy
7
×
clinical trials
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
fda
startups
deals
eli lilly
abbvie
biogen
bristol-myers squibb
investing
merck
nonalcoholic steatohepatitis
What
roundup
7
×
bio
drug
companies
annual
attention
biotech
days
growing
ipo
nash
news
week
acquisitions
ahead
alliance
alzheimer’s
ambien
american
announced
approval
approved
arena’s
asco
assessed
attendees
biogen’s
biopharmaceutical
bounty
bristol
buy
calls
camp’s
cancer
cash
ceo
changing
chicago
cig
city
Language
unset
Current search:
roundup
×
cancer
×
" cancer immunotherapy "
×
" new york top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More